Technical Analysis for GMDA - Gamida Cell Ltd.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 0.37 | 15.77% | 0.05 |
GMDA closed up 15.77 percent on Monday, March 18, 2024, on 2.6 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Mar 25
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Crossed Above 50 DMA | Bullish | 0.00% | |
Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Gapped Up | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Fell Below 50 DMA | Bearish | 13.85% | |
180 Bearish Setup | Bearish Swing Setup | 13.85% | |
Crossed Above 50 DMA | Bullish | 5.53% | |
Stochastic Buy Signal | Bullish | 5.53% |
Alert | Time |
---|---|
Rose Above Upper Bollinger Band | about 13 hours ago |
Upper Bollinger Band Resistance | about 13 hours ago |
Up 2 ATRs | about 14 hours ago |
60 Minute Opening Range Breakout | about 14 hours ago |
Possible Pocket Pivot | about 15 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/25/2024
Gamida Cell is a clinical stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company is leveraging its nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmacy Cyclacel Rare Serious Hematologic Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmacy Cyclacel Rare Serious Hematologic Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
S
SociableGnat503 8 months ago
Any thoughts on this one? It's insane of how much this has bled over the past several weeks.
T
TraderMike 8 months ago
My only thoughts are this seems to be a small biotech doing what small biotechs do. These things are incredibly news driven, especially the clinical stage ones.
View full discussion...
Indicator | Value |
---|---|
52 Week High | 2.51 |
52 Week Low | 0.2184 |
Average Volume | 2,922,550 |
200-Day Moving Average | 0.89 |
50-Day Moving Average | 0.35 |
20-Day Moving Average | 0.35 |
10-Day Moving Average | 0.34 |
Average True Range | 0.04 |
RSI (14) | 53.70 |
ADX | 13.37 |
+DI | 26.23 |
-DI | 17.18 |
Chandelier Exit (Long, 3 ATRs) | 0.32 |
Chandelier Exit (Short, 3 ATRs) | 0.42 |
Upper Bollinger Bands | 0.40 |
Lower Bollinger Band | 0.31 |
Percent B (%b) | 0.69 |
BandWidth | 23.77 |
MACD Line | -0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.0015 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.47 | ||||
Resistance 3 (R3) | 0.47 | 0.44 | 0.45 | ||
Resistance 2 (R2) | 0.44 | 0.41 | 0.44 | 0.45 | |
Resistance 1 (R1) | 0.40 | 0.40 | 0.42 | 0.40 | 0.44 |
Pivot Point | 0.37 | 0.37 | 0.38 | 0.37 | 0.37 |
Support 1 (S1) | 0.34 | 0.35 | 0.35 | 0.34 | 0.30 |
Support 2 (S2) | 0.31 | 0.33 | 0.30 | 0.29 | |
Support 3 (S3) | 0.27 | 0.31 | 0.29 | ||
Support 4 (S4) | 0.27 |